Retatrutide is a peptide investigated for its effects on body weight and metabolic health. It activates three hormone receptors: GLP-1, GIP and glucagon, which influence appetite, blood sugar regulation and energy use. Currently in the later stages of clinical trials, Retatrutide results include up to 28.3% weight loss compared to Tirzepatides 22.5% peak as well as a 37% greater liver fat reduction.
Already have an account? Log in
SEQUORA Retatrutide 20mg is an investigational research compound that activates GLP-1, GIP and glucagon receptors. Available in vial and prefilled pen formats, we offer a choice of formats to help with appetite regulation, glucose metabolism and energy balance.
The 20mg figure indicates the total stated Retatrutide content, not the concentration or amount delivered per withdrawal. Please visit the bottom of this page for dosage guidance and advice.
All of our products are third party laboratory tested to ensure both purity and verification of the peptide itself.
Retatrutide is an investigational compound that activates GIP, GLP-1 and glucagon receptors. Researchers are studying how these three pathways influence appetite, blood sugar regulation and energy metabolism.
Mounjaro contains tirzepatide, which activates GIP and GLP-1 receptors. Retatrutide also activates the glucagon receptor. This additional pathway is being investigated, but it does not automatically make retatrutide safer or more effective.
No. Retatrutide remains investigational and is not an approved weight-loss medicine. Its safety and effectiveness are being evaluated in clinical trials. Retatrutide sold by SEQUORA Peptides, although third party verified and tested is bought and used at your own risk.
Reported side effects include nausea, vomiting, diarrhoea and constipation. Trials have also observed increases in heart rate. Its longer-term safety is still being studied and trial findings cannot establish the safety of separately supplied research products.
Product information, handling and safety
What Temperature should I store my Retatrutide at?
What are the best practices for using Retatrutide safely?
The documentation behind Retatrutide and it's uses
Retatrutide is a peptide investigated for its effects on body weight and metabolic health. It activates three hormone receptors: GLP-1, GIP and glucagon, which influence appetite, blood sugar regulation and energy use. Currently in the later stages of clinical trials, Retatrutide results include up to 28.3% weight loss compared to Tirzepatides 22.5% peak as well as a 37% greater liver fat reduction.
Upon delivery store in a refridgerator between 2-8°C.
Avoid dropping or heavy-handling of your Retatrutide.
Please do not freeze your SEQUORA Retatrutide Pen as this can compromise the Retatrutide.
Your product has been shipped in secure packaging to prevent any potential issues however if you believe your peptides have been compromised contact us directly.
Your SEQUORA Retatrutide Pen will last 12 months from the date of manufacture providing you follow the storage instructions provided.
SEQUORA Retatrutide Vials before reconstitution can last up to 4 years at -5°C
Retatrutide can be kept at room temperature however it’s shelf life when held at this temperature reduces to 1-2 months.
Before handling your Retatrutide, needles or injection material, ensure your research area is clean and clear.
Wash your hands with warm water and soap and allow to dry fully before handling any SEQUORA products to prevent cross contamination or infection risks.
If at any point the cleanliness of your injection or environment is compromised, restart this step.
Never re-use or share needles/syringes. Ensure your needle tips or syringe is sealed and new before injection.
Before using your SEQUORA Retatrutide Pen, using an alcohol swab, wipe the tip of the cartridge after removing the lid to the pen.
If at any point you touch something unhygienic or potentially dirty, re-wash your hands and use new equipment.
Ensure that your needle tips, syringes and vials are safely disposed of post-use.
This could mean a sharps bin or safe container. Most needle tips and syringes have removable tops that can be replaced onto the used needle.
Try to keep your injection site clean for atleast 30 minutes post-injection to prevent infection risks.
Retatrutide remains investigational. Clinical trials have reported adverse effects, although not every person experiences these side effects its important to be aware of them.
Commonly reported effects in clinical trials
Digestive symptoms were generally mild to moderate, occurred particularly during dose escalation and caused some participants to stop treatment.
Other reported effects
Other important risks
Acute pancreatitis and gallbladder events were reported in the phase 2 obesity trial. An event occurring during a trial does not necessarily mean retatrutide caused it. Rare effects, long-term risks and interactions with other medicines remain incompletely understood.
When to seek medical help
Stop use and seek urgent medical attention for severe, persistent stomach pain, particularly if it spreads to the back, with or without vomiting. Seek prompt medical advice for repeated vomiting, inability to keep fluids down, reduced urination or a persistent racing or irregular heartbeat.
Call 999 immediately for difficulty breathing, sudden swelling of the lips, tongue or throat, chest pain or collapse. These are emergency warning signs, rather than a statement that each has been established as a retatrutide side effect.
Speak to a healthcare professional if symptoms persist, worsen or concern you. If participating in a clinical trial, report symptoms to the trial team.
About this information
This summary draws on retatrutide clinical trial data. Retatrutide has not been approved for human use. Findings from controlled trials do not establish the safety, quality or suitability of these products for human use and are not a substitute for medical advice.
Some mild digestive symptoms may improve with changes to eating and drinking habits. These measures have not been established as a specific mitigation protocol for retatrutide. They cannot prevent serious reactions or make an unlicensed product safe.
Nausea and heartburn
Constipation
Diarrhoea or vomiting
Altered skin sensation or increased heart rate
Changes in skin sensation and increased heart rate have been reported in retatrutide trials. Dietary changes are not an established treatment for these effects. Report new or persistent symptoms to a healthcare professional or your clinical trial team rather than attempting to manage them with supplements or additional medicines.
When to get advice
Contact a healthcare professional if symptoms persist or worsen. Seek prompt medical advice if you cannot keep fluids down, pass less urine, feel lightheaded or develop a persistent racing or irregular heartbeat. Tell them the product used, its stated strength and when symptoms began.
If participating in a clinical trial, contact the trial team before changing the dose or taking medicines to manage side effects.
Symptoms requiring urgent help
Stop use and seek urgent medical attention for severe, persistent stomach pain, particularly if it spreads to the back. Call 999 for difficulty breathing, sudden swelling of the lips, tongue or throat, chest pain or collapse. Do not try to manage these symptoms with dietary changes.
About this information
Retatrutide remains investigational. This information combines general symptom-management advice with awareness of effects reported in clinical trials. It does not establish the safety, quality or suitability of a SEQUORA product for human use and does not replace individual medical advice.
Retatrutide is studied to be administered once weekly. The schedule below summarises typical dosing information from clinical trials and peer research.
Pen strength: 20 mg in a final volume of 2.4 ml. Calculated dial settings assume delivery of 0.01 ml per dial unit. Check pen strength before every administration.
| Dose | Frequency | 20 mg pen dial setting | Stage and duration |
|---|---|---|---|
| 0.5 mg | Once weekly | 6 | Weeks 1 – 4: Starting dose for the first 4 weeks. |
| 1 mg | Once weekly | 12 | Weeks 5 – 8: Monitor effectiveness and side effects closely, only increase if needed. |
| 2 mg | Once weekly | 24 | Weeks 9 – 12: Monitor effectiveness and side effects closely, only increase if needed. |
| 3 mg | Once weekly | 36 | Weeks 13+: Monitor effectiveness and side effects closely, only increase if needed. |
| 4 mg | Once weekly | 48 | Weeks 13+: Monitor effectiveness and side effects closely, only increase if needed. |
| 5 mg | Once weekly | 60 | Weeks 13+: Monitor effectiveness and side effects closely, only increase if needed. |
Dose increases are not automatic
As retatrutide is still in clinical trials, dosing is individually dependant and not fixed. The goal should be to stay on the lowest dose possible while still maintaining the benefits and effects of retatrutide. If you notice hunger returning and your feeling of fullness leaving before your next injection, you can incrementally increase your dose.
Understanding the figures
Doses are expressed in milligrams per weekly administration. Each numbered dial of the pen delivers 0.01ml of liquid or 1 Unit. The SEQUORA 20mg Retatrutide Pen contains 2.4ml of reconstituted Retatrutide meaning every 1 dial = Approximately 0.0833 mg of Retatrutide.
Device limits and verification
The maximum dial setting is 60. “Exceeds single-dial capacity” means the listed dose cannot be delivered in one dialled administration using that strength. This table does not provide instructions for combining injections, if you feel you need a larger dose you should purchase the 40mg Retatrutide Pen instead.
Pen conversion reference: 20 mg in 2.4 ml
Calculated for a device delivering 0.01 ml per dial unit. This is a conversion reference, not a recommended dosing schedule.
| Amount | Pen dial setting | Amount | Pen dial setting |
|---|---|---|---|
| 0.25 mg | 3 | 2.75 mg | 33 |
| 0.50 mg | 6 | 3.00 mg | 36 |
| 0.75 mg | 9 | 3.25 mg | 39 |
| 1.00 mg | 12 | 3.50 mg | 42 |
| 1.25 mg | 15 | 3.75 mg | 45 |
| 1.50 mg | 18 | 4.00 mg | 48 |
| 1.75 mg | 21 | 4.25 mg | 51 |
| 2.00 mg | 24 | 4.50 mg | 54 |
| 2.25 mg | 27 | 4.75 mg | 57 |
| 2.50 mg | 30 | 5.00 mg | 60 |
Check before using this reference
These figures apply only to a 20 mg SEQUORA Retatrutide Pen with a final total volume of 2.4 ml, confirmed to deliver 0.01 ml per dial unit. They do not apply to other concentrations or device calibrations.
The figures describe calculated delivery, not independently measured output. They do not establish a safe dose, suitable frequency or suitability for injection.